Bristol-Myers Squibb BMY Other revenues — Total Revenues

Other product segments

Similar metrics at other companies

CMEOther Revenue — Total Revenues

$115.6M+9.2%

NWETotal Revenue — Total Revenues

$497.57M+6.6%

ACNConsulting Revenue — Total Revenues

$9.33B+3.6%

AEPOther Revenues — Total Revenues

$158M+19.7%

CUZOther — Total Revenues

$756K-88.9%

ESP

ESPRCollaboration revenue — Total Revenues

$36.71M+22.0%

FAQ

What is Bristol-Myers Squibb's other revenues — total revenues?

Bristol-Myers Squibb (BMY) reported other revenues — total revenues of $281M in Q2 2026.

How has Bristol-Myers Squibb's other revenues — total revenues changed year-over-year?

Bristol-Myers Squibb's other revenues — total revenues increased by 16.6% year-over-year, from $241M to $281M.

What is the long-term trend for Bristol-Myers Squibb's other revenues — total revenues?

Over 4 years (2021 to 2025), Bristol-Myers Squibb's other revenues — total revenues has grown at a 12.7% compound annual growth rate (CAGR), from $614M to $992M.

What does other revenues — total revenues mean?

This metric represents the portion of total consolidated revenue derived from secondary business activities, ancillary services, or non-core product lines that fall outside the company's primary therapeutic segments. It captures income streams such as royalty payments, contract manufacturing services, or divestiture-related adjustments that do not align with the core pharmaceutical portfolio. Monitoring this helps investors understand the contribution of non-operating or peripheral business units to the overall top-line performance.